News and Announcements
Future Generation Investment Forum announces Hamish Douglas interview
- Published April 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- The Future Generation Investment Forum being held on Thursday, 23 May 2019 at the Westin in Martin Place, Sydney.
- The Forum is delighted to announce that legendary investor Hamish Douglass, Chairman and Chief Investment Officer of Magellan will be in attendance and interviewed by the Australian Financial Review’s Chanticleer columnist Tony Boyd.
- Future Generation shareholders and newsletter subscribers are entitled to three free tickets and the Forum will be streamed live on the day for those who cannot attend.
The Future Generation Investment Forum being held on Thursday, 23 May 2019 is delighted to announce the appearance of legendary investor Hamish Douglass, Chairman and Chief Investment Officer of Magellan. We will be available for an exclusive interview by the Australian Financial Review’s Chanticleer columnist Tony Boyd.
The Forum will take place from 1.45pm – 3.15pm at The Westin, 1 Martin Place in Sydney. Future Generation shareholders and newsletter subscribers are entitled to three free tickets valued at $200 each. You are invited to claim your free tickets and register your attendance. The Forum will also be streamed via Livewire on the day.
About Future Generation Investment Company (ASX: FGX)
Shareholders with exposure to the best Australian fund managers without paying management or performance fees. Charities primarily focused on children and youth at risk with a consistent and growing stream of annual donations. Fund managers with a unique opportunity to make a positive difference to Australia’s future generations.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
